Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics

Department of Cardiology, University Hospital, Inselspital, Bern, Switzerland.

OBJECTIVES: We sought to study the effects of short-acting and long-acting nifedipine on the sympathetic nervous system (SNS), heart rate (HR) and blood pressure (BP) of normotensive subjects under baseline conditions and during SNS stimulation. BACKGROUND: Calcium channel antagonists in different pharmacokinetic formulations are widely used in patients with coronary artery disease or hypertension. Short-acting formulations activate the SNS, an action that may be disadvantageous in patients with coronary disease, especially if left ventricular function is impaired. The effects of slow-release formulations on the SNS are unknown. METHODS: We used microneurography to investigate the influence of nifedipine (5 mg; 10 mg; and slow-release [GITS], 60 mg) on muscle sympathetic nerve activity (MSA) and skin sympathetic nerve activity (SSA) in healthy volunteers. RESULTS: Peak plasma levels after short-acting and slow-release nifedipine were achieved within 60 min and 330 min, respectively. Short-acting (10 mg, n = 10) and slow-release (n = 10) nifedipine, but not placebo, markedly activated MSA and increased plasma norepinephrine; plasma endothelin increased only with slow-release nifedipine. HR increased after short-acting nifedipine, but not after nifedipine GITS. Nifedipine had no effect on SSA (n = 6). Blockade of cardiac sympathetic activity (with esmolol) led to similar decreases in HR with or without nifedipine, whereas parasympatholysis (with atropine) led to similar increases in HR with or without nifedipine. The cold pressor test markedly increased MSA in all treatment groups and further increased MSA beyond the increase induced by nifedipine. CONCLUSIONS: Nifedipine markedly increased MSA, but not SSA, independently of drug release formulation. In contrast, HR increased with short-acting, but not with slow-release, nifedipine. Therefore, nifedipine activates cardiac and peripheral sympathetic nerves differently depending on pharmacokinetics. These effects of nifedipine may be disadvantageous in cardiac patients with increased sympathetic activity or congestive heart failure, or both.

This article has been cited by other articles:

				A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF]

				I. Sudano, L. Spieker, C. Binggeli, F. Ruschitzka, T. F. Luscher, G. Noll, and R. Corti Coffee Blunts Mental Stress-Induced Blood Pressure Increase in Habitual but Not in Nonhabitual Coffee Drinkers Hypertension, September 1, 2005; 46(3): 521 - 526. [Abstract] [Full Text] [PDF]

				G. Eisenhofer, D. S. Goldstein, M. M. Walther, P. Friberg, J. W. M. Lenders, H. R. Keiser, and K. Pacak Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2656 - 2666. [Abstract] [Full Text] [PDF]

				G. Grassi, G. Seravalle, C. Turri, G. Bolla, and G. Mancia Short-Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension Hypertension, March 1, 2003; 41(3): 558 - 562. [Abstract] [Full Text] [PDF]

				M. Hausberg, M. Kosch, P. Harmelink, M. Barenbrock, H. Hohage, K. Kisters, K. H. Dietl, and K. H. Rahn Sympathetic Nerve Activity in End-Stage Renal Disease Circulation, October 8, 2002; 106(15): 1974 - 1979. [Abstract] [Full Text] [PDF]

				C. Binggeli, R. Corti, I. Sudano, T. F. Luscher, and G. Noll Effects of Chronic Calcium Channel Blockade on Sympathetic Nerve Activity in Hypertension Hypertension, April 1, 2002; 39(4): 892 - 896. [Abstract] [Full Text] [PDF]

				L. E. Spieker, R. Corti, C. Binggeli, T. F. Luscher, and G. Noll Baroreceptor dysfunction induced by nitric oxide synthase inhibition in humans J. Am. Coll. Cardiol., July 1, 2000; 36(1): 213 - 218. [Abstract] [Full Text] [PDF]

				R. Corti, C. Binggeli, I. Sudano, L. E. Spieker, R. R. Wenzel, T. F. Luscher, and G. Noll The Beauty and the Beast: Aspects of the Autonomic Nervous System Physiology, June 1, 2000; 15(3): 125 - 129. [Abstract] [Full Text] [PDF]

				P. P. Murzenok, B. S. Huang, and F. H. H. Leenen Sympathoinhibition by Central and Peripheral Infusion of Nifedipine in Spontaneously Hypertensive Rats Hypertension, February 1, 2000; 35(2): 631 - 636. [Abstract] [Full Text] [PDF]

				K. Narkiewicz, M. Kato, B. G. Phillips, C. A. Pesek, D. E. Davison, and V. K. Somers Nocturnal Continuous Positive Airway Pressure Decreases Daytime Sympathetic Traffic in Obstructive Sleep Apnea Circulation, December 7, 1999; 100(23): 2332 - 2335. [Abstract] [Full Text] [PDF]

				K. Sakata, M. Shirotani, H. Yoshida, R. Nawada, K. Obayashi, K. Togi, and N. Miho Effects of Amlodipine and Cilnidipine on Cardiac Sympathetic Nervous System and Neurohormonal Status in Essential Hypertension Hypertension, June 1, 1999; 33(6): 1447 - 1452. [Abstract] [Full Text] [PDF]

				R. R. Wenzel, L. Spieker, S. Qui, S. Shaw, T. F. Luscher, and G. Noll I1-Imidazoline Agonist Moxonidine Decreases Sympathetic Nerve Activity and Blood Pressure in Hypertensives Hypertension, December 1, 1998; 32(6): 1022 - 1027. [Abstract] [Full Text] [PDF]

				K. Sakata, M. Shirotani, H. Yoshida, and C. Kurata Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension J. Am. Coll. Cardiol., August 1, 1998; 32(2): 438 - 443. [Abstract] [Full Text] [PDF]